Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
NVP-BAW2881
Cat. No.:
0225LY-1287
Purity:
≥99%
Identity:
Confirmed by NMR.
Size:
Add to basket
Product Overview
Description:
NVP-BAW2881 is a selective VEGFR inhibitor effective in mitigating both acute and chronic skin inflammation.
Synonym:
861875-60-7; BAW2881; 6-((2-aminopyrimidin-4-yl)oxy)-N-(3-(trifluoromethyl)phenyl)-1-naphthamide; 6-(2-aminopyrimidin-4-yl)oxy-N-[3-(trifluoromethyl)phenyl]naphthalene-1-carboxamide; 6-[(2-aminopyrimidin-4-yl)oxy]-N-[3-(trifluoromethyl)phenyl]naphthalene-1-carboxamide; 6-[(2-amino-4-pyrimidinyl)oxy]-N-[3-(trifluoromethyl)phenyl]-1-naphthalenecarboxamide
CAS No.:
861875-60-7
Compound CID:
16004702
Formula:
C22H15F3N4O2
Formula Weight:
424.38
Specification
Targets&IC50:
VEGFR2 (human): 9 nM; B-Raf (V599E): 76 nM; VEGF2 (mouse): 165 nM; c-ABL: 99 nM; C-Raf1: 24 nM
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
NVP-BAW2881 can be used in dermatological research to study the inhibition of VEGFR and its potential in treating inflammatory skin diseases.
Library Information
Target:
Raf; VEGFR; Bcr-Abl
Receptor:
B-Raf (V599E); c-Abl; C-Raf-1; VEGFR2
Pathways:
Tyrosine kinase/adaptors; MAPK; Angiogenesis; Cytoskeletal signaling
Plate Number:
AOCL-17
Plate Location:
e4
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
78 mg/mL; 183.8 mM
Water Max Solubility:
<1 mg/mL (insoluble or slightly soluble)
Ethanol Max Solubility:
16 mg/mL; 37.7 mM
ALogP:
4.56
HBA_Count:
4
HBD_Count:
2
Rotatable Bond:
5
